<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; WHO</title>
	<atom:link href="http://www.tapanray.in/tag/who/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>India’s Drug Quality Concerns: Is Light At The End of The Tunnel In Sight Now?</title>
		<link>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now</link>
		<comments>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/#comments</comments>
		<pubDate>Mon, 07 Aug 2023 00:00:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[action]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[end]]></category>
		<category><![CDATA[events]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[light]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[QR]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tunnel]]></category>
		<category><![CDATA[two=pronged]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10805</guid>
		<description><![CDATA[A brief chronology of some recent events on issues pertaining to patient-health-safety with drugs, as captured below, would possibly generate a mixed feeling for many. This includes a serious concern about, especially generic drug quality safety standards in India, on the one &#8230; <a href="http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cacophony Over Coronavirus Lockdown</title>
		<link>http://www.tapanray.in/cacophony-over-coronavirus-lockdown/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=cacophony-over-coronavirus-lockdown</link>
		<comments>http://www.tapanray.in/cacophony-over-coronavirus-lockdown/#comments</comments>
		<pubDate>Mon, 30 Mar 2020 00:00:57 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[cacophony]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid19]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[equipment]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[kit]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[masks]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[options]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[PPE]]></category>
		<category><![CDATA[preparedness]]></category>
		<category><![CDATA[protective]]></category>
		<category><![CDATA[rationale]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recommendations]]></category>
		<category><![CDATA[religious]]></category>
		<category><![CDATA[sanitizer]]></category>
		<category><![CDATA[solutions]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[testing]]></category>
		<category><![CDATA[tests]]></category>
		<category><![CDATA[viruses]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9943</guid>
		<description><![CDATA[Currently, the entire India is trying hard to comply with the 21-day lockdown of the country, as communicated by Prime Minister Narendra Modi to the nation at 8 pm on March 24, 2020. The very next day,  while addressing his parliamentary &#8230; <a href="http://www.tapanray.in/cacophony-over-coronavirus-lockdown/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/cacophony-over-coronavirus-lockdown/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>SCM: Embracing Technology For Patients’ Safety</title>
		<link>http://www.tapanray.in/scm-embracing-technology-for-patients-safety/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=scm-embracing-technology-for-patients-safety</link>
		<comments>http://www.tapanray.in/scm-embracing-technology-for-patients-safety/#comments</comments>
		<pubDate>Sun, 17 Dec 2017 23:40:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[Combiflam]]></category>
		<category><![CDATA[D-Cold]]></category>
		<category><![CDATA[DGFT]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[DSCSA]]></category>
		<category><![CDATA[embracing]]></category>
		<category><![CDATA[harnessing]]></category>
		<category><![CDATA[identifier]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[SCM]]></category>
		<category><![CDATA[serialization]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[trace]]></category>
		<category><![CDATA[Track]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8646</guid>
		<description><![CDATA[Supply Chain Management (SCM) in the pharma industry is generally perceived as a logistic function, just in most other industries, involving the distribution of medicines from manufacturing plants, right up to pharma distributors. Thereafter, it becomes the responsibility of the &#8230; <a href="http://www.tapanray.in/scm-embracing-technology-for-patients-safety/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/scm-embracing-technology-for-patients-safety/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Digiceuticals’: A Force Multiplier to Contain Chronic Diseases</title>
		<link>http://www.tapanray.in/digiceuticals-a-force-multiplier-to-contain-chronic-diseases/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=digiceuticals-a-force-multiplier-to-contain-chronic-diseases</link>
		<comments>http://www.tapanray.in/digiceuticals-a-force-multiplier-to-contain-chronic-diseases/#comments</comments>
		<pubDate>Sun, 22 Oct 2017 23:30:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[app]]></category>
		<category><![CDATA[chronic]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[digiceuticals]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[disorders]]></category>
		<category><![CDATA[epidemic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[NCD]]></category>
		<category><![CDATA[pull]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[smartphone]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[suppliers]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8373</guid>
		<description><![CDATA[There is a growing need for more effective prevention, treatment or management of many serious Noninfectious Chronic Diseases (NCDs), with greater safety and at a lesser cost. As a major step in this direction, ‘digiceuticals’ or ‘digital therapeutics’ are now &#8230; <a href="http://www.tapanray.in/digiceuticals-a-force-multiplier-to-contain-chronic-diseases/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/digiceuticals-a-force-multiplier-to-contain-chronic-diseases/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Draft Pharma Policy 2017 And Branded Generics</title>
		<link>http://www.tapanray.in/draft-pharma-policy-2017-and-branded-generics/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=draft-pharma-policy-2017-and-branded-generics</link>
		<comments>http://www.tapanray.in/draft-pharma-policy-2017-and-branded-generics/#comments</comments>
		<pubDate>Sun, 27 Aug 2017 23:55:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[Bioavailability]]></category>
		<category><![CDATA[bioequivalence]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[GLP]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[name]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[unbranded]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[WOW]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8385</guid>
		<description><![CDATA[In its first reading, the 18-page draft Pharma Policy, 2017 gives me a sense that the Government has followed the much-desired principle of ‘walk the talk’, especially in some key areas. One such space is what Prime Minister Modi distinctly &#8230; <a href="http://www.tapanray.in/draft-pharma-policy-2017-and-branded-generics/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/draft-pharma-policy-2017-and-branded-generics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dry New Antibiotic Pipeline: Increasing Incidence Of Deadly Antibiotic Resistance</title>
		<link>http://www.tapanray.in/dry-new-antibiotic-pipeline-increasing-incidence-of-deadly-antibiotic-resistance/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=dry-new-antibiotic-pipeline-increasing-incidence-of-deadly-antibiotic-resistance</link>
		<comments>http://www.tapanray.in/dry-new-antibiotic-pipeline-increasing-incidence-of-deadly-antibiotic-resistance/#comments</comments>
		<pubDate>Mon, 23 Jan 2017 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[antibiotic]]></category>
		<category><![CDATA[Antimicrobial]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[dry]]></category>
		<category><![CDATA[iChip]]></category>
		<category><![CDATA[imidazolium oligomers]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[pew]]></category>
		<category><![CDATA[pipeline]]></category>
		<category><![CDATA[PLOS]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[resistance]]></category>
		<category><![CDATA[Singapore]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Teixobactin]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8054</guid>
		<description><![CDATA[On January 13, 2017, &#8216;The Telegraph&#8217; quoting the ‘Centers for Disease Control and Prevention (CDC)’ reported that a woman in Nevada was killed by a superbug that proved resistant to every antibiotic available in the United States (US). She was in her &#8230; <a href="http://www.tapanray.in/dry-new-antibiotic-pipeline-increasing-incidence-of-deadly-antibiotic-resistance/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/dry-new-antibiotic-pipeline-increasing-incidence-of-deadly-antibiotic-resistance/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mental Health Problem: A Growing Concern In The Healthcare Space Of India</title>
		<link>http://www.tapanray.in/mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india</link>
		<comments>http://www.tapanray.in/mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india/#comments</comments>
		<pubDate>Mon, 16 Jan 2017 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Alzheimer's]]></category>
		<category><![CDATA[anxiety]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[dementia]]></category>
		<category><![CDATA[depression]]></category>
		<category><![CDATA[Development Goals]]></category>
		<category><![CDATA[disorder]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[illness]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[Lok]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[mental]]></category>
		<category><![CDATA[nation]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Rajya]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sabha]]></category>
		<category><![CDATA[SDG]]></category>
		<category><![CDATA[series]]></category>
		<category><![CDATA[stigma]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8049</guid>
		<description><![CDATA[A thud! Something fell from high above! In no time, a bright young life of just a 32-year-old highly accomplished professional &#8211; a widely admired soul, vanished in the thin year, for good, mostly unnoticed in the quiet neighborhood, initially. &#8230; <a href="http://www.tapanray.in/mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Counterfeit Drugs In India: A Malady Much Deeper</title>
		<link>http://www.tapanray.in/counterfeit-drugs-in-india-a-malady-much-deeper/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=counterfeit-drugs-in-india-a-malady-much-deeper</link>
		<comments>http://www.tapanray.in/counterfeit-drugs-in-india-a-malady-much-deeper/#comments</comments>
		<pubDate>Sun, 23 Oct 2016 23:39:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[anti-counterfeit]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[deeper]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intent]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[malady]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[substandard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[types]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7907</guid>
		<description><![CDATA[Many debates and discussions continue being lined up in India almost regularly, generally by the pharma trade associations, besides a few others, on the issue of counterfeit drugs. A good number of these events are sponsored by the global and &#8230; <a href="http://www.tapanray.in/counterfeit-drugs-in-india-a-malady-much-deeper/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/counterfeit-drugs-in-india-a-malady-much-deeper/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Reticence Around Unveiling Clinical Trials</title>
		<link>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=reticence-around-unveiling-clinical-trials</link>
		<comments>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/#comments</comments>
		<pubDate>Mon, 17 Oct 2016 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Atorvastatin]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[EFPIA]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[GVK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[legalities]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reticence]]></category>
		<category><![CDATA[Semler]]></category>
		<category><![CDATA[statin]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[Unveiling]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7886</guid>
		<description><![CDATA[While scanning through various publications, we now get to know, almost at regular intervals, about new clinical trials capturing the newer ways of treating different ailments. Such information instils an invigorating hope in the minds of doctors and the patients &#8230; <a href="http://www.tapanray.in/reticence-around-unveiling-clinical-trials/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An Evolving Paradigm of ‘Price-Value Model’ Of Pharma Value Delivery System</title>
		<link>http://www.tapanray.in/an-evolving-paradigm-of-price-value-model-of-pharma-value-delivery-system/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-evolving-paradigm-of-price-value-model-of-pharma-value-delivery-system</link>
		<comments>http://www.tapanray.in/an-evolving-paradigm-of-price-value-model-of-pharma-value-delivery-system/#comments</comments>
		<pubDate>Mon, 09 May 2016 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[alipogene]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[DNA]]></category>
		<category><![CDATA[Ebola]]></category>
		<category><![CDATA[evolving]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[Glybera]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[map]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[Price-Value]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[tiparvovec)]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7631</guid>
		<description><![CDATA[May 4, 2016 edition of the ‘MIT Technology Review’ published an interesting article carrying the headline, “The World’s Most Expensive Medicine Is a Bust”. The obvious question that floats at the top of mind: What is this most expensive drug &#8230; <a href="http://www.tapanray.in/an-evolving-paradigm-of-price-value-model-of-pharma-value-delivery-system/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-evolving-paradigm-of-price-value-model-of-pharma-value-delivery-system/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
